BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36823323)

  • 1. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.
    Feils AS; Erbe AK; Birstler J; Kim K; Hoch U; Currie SL; Nguyen T; Yu D; Siefker-Radtke AO; Tannir N; Tolaney SM; Diab A; Sondel PM
    Cancer Immunol Immunother; 2023 Jul; 72(7):2099-2111. PubMed ID: 36823323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
    Erbe AK; Wang W; Carmichael L; Hoefges A; Grzywacz B; Reville PK; Ranheim EA; Hank JA; Kim K; Seo S; Mendonca EA; Song Y; Kenkre VP; Hong F; Gascoyne RD; Paietta E; Horning SJ; Miller JS; Kahl B; Sondel PM
    J Immunother Cancer; 2019 Mar; 7(1):70. PubMed ID: 30871628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
    Erbe AK; Wang W; Carmichael L; Kim K; Mendonça EA; Song Y; Hess D; Reville PK; London WB; Naranjo A; Hank JA; Diccianni MB; Reisfeld RA; Gillies SD; Matthay KK; Cohn SL; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Gilman AL; Yu AL; Sondel PM
    Clin Cancer Res; 2018 Jan; 24(1):189-196. PubMed ID: 28972044
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.
    Beksac K; Beksac M; Dalva K; Karaagaoglu E; Tirnaksiz MB
    PLoS One; 2015; 10(7):e0132526. PubMed ID: 26181663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
    Wang W; Erbe AK; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Weiss JM; Mier J; Panka D; McDermott DF; Sondel PM
    Cancer Immunol Immunother; 2016 Dec; 65(12):1523-1532. PubMed ID: 27695964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
    Delgado DC; Hank JA; Kolesar J; Lorentzen D; Gan J; Seo S; Kim K; Shusterman S; Gillies SD; Reisfeld RA; Yang R; Gadbaw B; DeSantes KB; London WB; Seeger RC; Maris JM; Sondel PM
    Cancer Res; 2010 Dec; 70(23):9554-61. PubMed ID: 20935224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort.
    Ishida Y; Nakashima C; Kojima H; Tanaka H; Fujimura T; Matsushita S; Yamamoto Y; Yoshino K; Fujisawa Y; Otsuka A; Kabashima K
    Sci Rep; 2018 Oct; 8(1):15962. PubMed ID: 30374122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
    Erbe AK; Wang W; Reville PK; Carmichael L; Kim K; Mendonca EA; Song Y; Hank JA; London WB; Naranjo A; Hong F; Hogarty MD; Maris JM; Park JR; Ozkaynak MF; Miller JS; Gilman AL; Kahl B; Yu AL; Sondel PM
    Front Immunol; 2017; 8():675. PubMed ID: 28659916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
    Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
    Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals.
    Naumova E; Mihaylova A; Stoitchkov K; Ivanova M; Quin L; Toneva M
    Cancer Immunol Immunother; 2005 Feb; 54(2):172-8. PubMed ID: 15248031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of killer cell immunoglobulin-like receptors and their human leukocyte antigen-ligands gene polymorphisms in Iranian patients with systemic lupus erythematosus.
    Akhtari M; Farazmand A; Mahmoudi M; Akbarian M; Ahmadzadeh N; Mirkazemi Z; Mostafaei S; Jamshidi AR
    Lupus; 2016 Oct; 25(11):1244-53. PubMed ID: 26989167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Leukocyte Antigen-C Genotype and Killer Immunoglobulin-like Receptor-Ligand Matching in Korean Living Donor Liver Transplantation.
    Lee H; Park KH; Park HS; Ryu JH; Lim J; Kim Y; Na GH; Kim DG; Oh EJ
    Ann Lab Med; 2017 Jan; 37(1):45-52. PubMed ID: 27834065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of killer cell immunoglobulin-like receptors and their cognate HLA class I ligands with susceptibility to acute myeloid leukemia in Iranian patients.
    Mirzazadeh S; Bemani P; Halimi H; Sanaee MN; Karami N; Ramzi M; Farjadian S
    Sci Rep; 2023 Jul; 13(1):11456. PubMed ID: 37454198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes to Predict the Occurrence of Acute Allograft Rejection after Kidney Transplantation.
    Jafari D; Nafar M; Yekaninejad MS; Abdolvahabi R; Lesan Pezeshki M; Razaghi E; Amirzargar AA
    Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):245-255. PubMed ID: 28732438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of killer cell immunoglobulin-like receptor (KIR) genes and human leukocyte antigen (HLA) class I ligands on predisposition or protection against prostate cancer.
    Roshan Zamir M; Ariafar A; Ghaderi A; Amirzargar A
    Immunobiology; 2023 Mar; 228(2):152319. PubMed ID: 36599262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study.
    Varbanova VP; Mihailova S; Naumova E; Mihaylova AP
    Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
    Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased frequencies of the killer immunoglobulin-like receptor genes KIR2DL2 and KIR2DS2 are associated with neuroblastoma.
    Keating SE; Ní Chorcora C; Dring MM; Stallings RL; O'Meara A; Gardiner CM
    Tissue Antigens; 2015 Sep; 86(3):172-7. PubMed ID: 26202659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage.
    Canossi A; Aureli A; Del Beato T; Rossi P; Franceschilli L; De Sanctis F; Sileri P; di Lorenzo N; Buonomo O; Lauro D; Venditti A; Sconocchia G
    J Transl Med; 2016 Aug; 14(1):239. PubMed ID: 27519478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis.
    Mahmoudi M; Fallahian F; Sobhani S; Ghoroghi S; Jamshidi A; Poursani S; Dolati M; Hosseinpour Z; Gharibdoost F
    Clin Rheumatol; 2017 Apr; 36(4):853-862. PubMed ID: 28120169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.